RE:RE:RE:RE:Why did the Study fail?Yes. They should. However, this release is very contradictory.
On one hand, it not good and on the other its hopeful.
Details are very sparse. Question at this point is are:
1. What is the make up of the DSMB? Data Safety Monitoring Board (DSMB), an independent committee appointed by CAB to advise on the trials. to discontinue the clinical trial after conducting a futility evaluation for interim progression free survival in study subjects.
2. What are the actual results of the futility evaluation? No data is being shared by CAB and QPT
3. What (if any) impact can QPT have on outcome? Quest is also in discussions with CABM on options available for Quest to continue to support the oregovomab clinical program.
Regardless, QPT shareholders have reasons to be very suspicious of CAB. These are the people who bought a product they never paid for. Also, the impact of this news on QPT valuation is clear.
And the ramification on future payment is even dimmer now. This lead to the possibility that QPT is a potential takeover target that can be acquired for very cheap. And the payments then....gone?